SEC
RNAM

Seven Eight Capital’s Avidity Biosciences RNAM Stock Holding History

Seven Eight Capital’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-82,168
Closed -$3.77M – 507
2024
Q3 		$3.77M Buy
+82,168
New +$3.57M 0.34% 56

Other funds holding RNAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Seven Eight Capital's RNAM Position: Q4 2024 in Review

Seven Eight Capital sold out of Avidity Biosciences (RNAM) in Q4 2024, closing a stake of 82,168 shares — an estimated $3.77M sold.

Seven Eight Capital first reported a position in RNAM in Q3 2024 and held it in 1 quarter. The position peaked at $3.77M in Q3 2024. 236 funds tracked by Wall St. Rank hold RNAM as of Q4 2024.

  • Seven Eight Capital reported no remaining Avidity Biosciences position as of Q4 2024 after selling out during the quarter.
  • Seven Eight Capital sold 82,168 Avidity Biosciences shares in Q4 2024, an estimated $3.77M.
  • Seven Eight Capital first reported a position in Avidity Biosciences in Q3 2024 and held it in 1 quarter.
  • Seven Eight Capital's Avidity Biosciences position peaked at $3.77M in Q3 2024.
  • 236 funds tracked by Wall St. Rank held Avidity Biosciences as of Q4 2024.

Based on Seven Eight Capital's 13F filing for Q4 2024.